genetically modified myeloid cells expressing IL-12 (National Cancer Institute)

N/A

Report date: 2025/03/20 16:01:13

Base Information

Drug Namegenetically modified myeloid cells expressing IL-12 (National Cancer Institute)
Drug Alias NameGEMys
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionInterleukin-12 receptor stimulants
TargetsInterleukin-12 receptor
Therapy Area/IndicationsLung NeoplasmsPancreatic NeoplasmsRhabdomyosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsPancreatic NeoplasmsRhabdomyosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A